A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)
Status:
Completed
Trial end date:
2020-06-03
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to
evaluate the safety and efficacy of fremanezumab in adult participants aged 18 to 70 years,
inclusive, for the prevention of PTH. The study will include a double-blind (DB) treatment
period (12 weeks) and an open-label (OL) treatment period (12 weeks).
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.